Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Safety and Dose Study of GRN163L Administered Weekly to Treat Patients With Chronic Lymphocytic Leukemia (CLL)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Pharmaceutical / Industry
GRN163L CP04-151
NCT00124189
2.
A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Pharmaceutical / Industry
GRN163L CP14A010
NCT00732056
3.
Safety and Dose Study of GRN163L Administered to Patients With Solid Tumor Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 and over
Pharmaceutical / Industry
GRN163L CP05-101
NCT00310895
4.
Safety and Dose Study of GRN163L With Paclitaxel and Carboplatin to Treat Patients With Advanced or Metastatic Non Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 and over
Pharmaceutical / Industry
GRN163L CP14A005
NCT00510445
5.
Safety and Dose Study of GRN163L Administered Weekly to Treat Patients With Refractory or Relapsed Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 and over
Pharmaceutical / Industry
GRN163L CP14A004
NCT00594126
6.
Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Approved-not yet active
18 and over
Pharmaceutical / Industry
GRN163L CP14A011
NCT00718601
Select All on One Page
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute